Published on 8 Feb 2024 on GuruFocus.com via Yahoo Finance
Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway
Net Loss: Reported a net loss of $51.1 million for the quarter ended December 31, 2023.Research and Development Expenses: Increased to $42.8 million from $30.3 million in the same period last year.Operating Expenses: Total operating expenses rose to $56.5 million compared to $41.6 million year-over-year.Cash Position: Cash, cash equivalents, and short-term investments totaled $466.4 million.Financial Outlook: Replimune expects existing cash to fund operations into the second half of 2026.RP1 and RP2 Updates: Progress in clinical trials with plans for a BLA submission for RP1 in 2H 2024 and a new trial for RP2.
Warning! GuruFocus has detected 2 Warning Sign with REPL.